Old Web
English
Sign In
Acemap
>
authorDetail
>
Mark C. Totoritis
Mark C. Totoritis
Medicine
Diabetes mellitus
Systemic lupus erythematosus
Immunology
Placebo
5
Papers
247
Citations
0.01
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial
2014
Annals of Allergy Asthma & Immunology
Marc A. Riedl
Jonathan A. Bernstein
Henry Li
Avner Reshef
William R. Lumry
Dumitru Moldovan
Henriette Farkas
Robyn J. Levy
James R. Baker
Yun Hardiman
Mark C. Totoritis
Anurag Relan
Marco Cicardi
Show All
Source
Cite
Save
Citations (51)
Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study.
2014
Journal of Travel Medicine
Herbert L. DuPont
Ann Katrin Petersen
Jeff Zhao
Arley Mundt
Zhi-Dong Jiang
Stephan Miller
Jose Flores
Reshma Shringarpure
Luigi Moro
Robert Bagin
E. David Ballard
Mark C. Totoritis
Show All
Source
Cite
Save
Citations (19)
IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus.
1995
Journal of Immunology
Robert L. Rubin
R. W. Burlingame
J E Arnott
Mark C. Totoritis
Edward M. McNally
A. D. Johnson
Show All
Source
Cite
Save
Citations (38)
Drug-induced lupus. Genetic, clinical, and laboratory features.
1985
Postgraduate Medicine
Mark C. Totoritis
Robert L. Rubin
Show All
Source
Cite
Save
Citations (30)
1